Literature DB >> 34550576

Employing the Operational Model to Measure System-Independent OTR Efficacy.

Kiyan Afzali1, Mark Connor2.   

Abstract

Ideally, pharmacological analysis is based on quantitative measurements applied toward unveiling biological mechanisms and guiding medicinal chemistry efforts in drug discovery and basic research. The most robust analysis frameworks generate findings which can be dissociated from the specific experimental setting to provide insights of a broader scope. With insufficient efficacy being the leading cause of drug failures in late-stage clinical trials, more rigorous preclinical definitions might assist in better translation. This chapter details a new method for accessing the Black and Leff operational model of agonism using a stable Flp-In™ T-REx™ HEK293 cell line under tetracycline-dependent control of OTR expression. We cover steps for performing the Gq-coupled HTRF® IP-One assay, curve-fitting data, calculating and statistically representing system-independent drug activity, predicting responses in different sensitivities, and plotting of multivariate analyses.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Black and Leff operational model of agonism; Drug discovery and development; G protein-coupled receptor (GPCR); IP-One (IP1) accumulation assay; Oxytocin receptor (OTR); Pharmacodynamics; Tetracycline-inducible expression (Flp-In™ T-REx™)

Mesh:

Substances:

Year:  2022        PMID: 34550576     DOI: 10.1007/978-1-0716-1759-5_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

Review 1.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Authors:  Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

Review 2.  Theoretical Aspects of GPCR-Ligand Complex Pharmacology.

Authors:  Terry Kenakin
Journal:  Chem Rev       Date:  2016-02-09       Impact factor: 60.622

Review 3.  Targeting the Oxytocin System: New Pharmacotherapeutic Approaches.

Authors:  Damien Gulliver; Eryn Werry; Tristan A Reekie; Timothy A Katte; William Jorgensen; Michael Kassiou
Journal:  Trends Pharmacol Sci       Date:  2018-11-30       Impact factor: 14.819

4.  Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm.

Authors:  Christopher J Langmead
Journal:  J Biomol Screen       Date:  2007-05-03

Review 5.  Prescient Indices of Activity: The Application of Functional System Sensitivity to Measurement of Drug Effect.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2019-05-17       Impact factor: 14.819

6.  What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2014-07-17       Impact factor: 14.819

7.  Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors.

Authors:  William T Jorgensen; Damien W Gulliver; Timothy A Katte; Eryn L Werry; Tristan A Reekie; Mark Connor; Michael Kassiou
Journal:  Eur J Med Chem       Date:  2017-10-23       Impact factor: 6.514

Review 8.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

9.  Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.

Authors:  William T Jorgensen; Damien W Gulliver; Eryn L Werry; Tristan Reekie; Mark Connor; Michael Kassiou
Journal:  Eur J Med Chem       Date:  2015-12-13       Impact factor: 6.514

10.  Applications and limitations of fitting of the operational model to determine relative efficacies of agonists.

Authors:  Jan Jakubík; Alena Randáková; Vladimír Rudajev; Pavel Zimčík; Esam E El-Fakahany; Vladimír Doležal
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.